Search

Your search keyword '"Yuno, Tsutomu"' showing total 23 results
Start Over Author "Yuno, Tsutomu"
23 results on '"Yuno, Tsutomu"'

1. A CASE OF CONGENITAL UNILATERAL ABSENCE OF THE VAS DEFERENS WITH SUSPECTED IPSILATERAL RENAL AGENESIS

Author

Harada, Junki, primary, Kihara, Toshiharu, additional, Kawada, Ken, additional, Gono, Suzuna, additional, Sagawa, Ryo, additional, Kondo, Tsubasa, additional, Yuno, Tsutomu, additional, Shida, Yohei, additional, Hakariya, Tomoaki, additional, Kosaka, Taiichiro, additional, Dateki, Sumito, additional, Miyata, Yasuyoshi, additional, and Sakai, Hideki, additional

Published
2021
Full Text
View/download PDF

2. Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1

Author

Mukae, Yuta, Miyata, Yasuyoshi, Nakamura, Yuichiro, Araki, Kyohei, Otsubo, Asato, Yuno, Tsutomu, Mitsunari, Kensuke, Matsuo, Tomohiro, Ohba, Kojiro, Sakai, Hideki, Mukae, Yuta, Miyata, Yasuyoshi, Nakamura, Yuichiro, Araki, Kyohei, Otsubo, Asato, Yuno, Tsutomu, Mitsunari, Kensuke, Matsuo, Tomohiro, Ohba, Kojiro, and Sakai, Hideki

Abstract

c-Met is a receptor tyrosine kinase that binds a specific ligand, namely hepatocyte growth factor (HGF). The HGF/c-Met system is important for malignant aggressiveness in various types of cancer, including bladder cancer (BC). However, although phosphorylation is the essential step required for biological activation of c-Met, pathological roles of phosphorylated c-Met at the clinical and molecular levels in patients with BC are not fully understood. In the present study, the expression levels of c-Met and the phosphorylation of two of its tyrosine residues (pY1234/pY1235 and pY1349) were immunohistochemically examined in 185 BC tissues. The associations between these expression levels and cancer cell invasion, metastasis, and cyclooxygenase-2 (COX-2), heme oxygenase-1 (HO-1), VEGF-A and programmed death ligand 1 (PD-L1) levels were investigated. c-Met was associated with muscle invasion (P=0.021), as well as the expression levels of HO-1 (P=0.028) and PD-L1 (P<0.001), whereas pY1349 c-Met was associated with muscle invasion (P=0.003), metastasis (P=0.025), and COX-2 (P=0.017), HO-1 (P=0.031) and PD-L1 (P=0.001) expression. By contrast, pY1234/1235 c-Met was associated with muscle invasion and metastasis (P=0.006 and P=0.012, respectively), but not with the panel of cancer-associated molecules. Furthermore, COX-2 and PD-L1 expression were associated with muscle invasion and metastasis, respectively (P=0.045 and P=0.036, respectively). Hence, c-Met serves important roles in muscle invasion by regulating HO-1 and PD-L1, whereas its phosphorylation at Y1349 is associated with muscle invasion and metastasis via the regulation of COX-2, HO-1 and PD-L1 in patients with BC. Furthermore, phosphorylation at Y1234/1235 may lead to muscle invasion and metastasis via alternate mechanisms associated with c-Met and pY1349 c-Met., Oncology Letters, 20(1), pp.135-144; 2020

Published
2020

4. Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators

Author

Yuno, Tsutomu, primary, Miyata, Yasuyoshi, additional, Mukae, Yuta, additional, Otsubo, Asato, additional, Mitsunari, Kensuke, additional, Matsuo, Tomohiro, additional, Ohba, Kojiro, additional, and Sakai, Hideki, additional

Published
2020
Full Text
View/download PDF

6. [Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑&alpha; and TGF‑&beta; in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Author

Miyata, Yasuyoshi, primary, Araki, Kyohei, additional, Ohba, Kojiro, additional, Mastuo, Tomhiro, additional, Nakamura, Yuichiro, additional, Yuno, Tsutomu, additional, Mukai, Yuta, additional, Otsubo, Asato, additional, Mitsunari, Kensuke, additional, Mochizuki, Yasushi, additional, and Sakai, Hideki, additional

Published
2020
Full Text
View/download PDF

7. Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑&alpha; and TGF‑&beta; in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Author

Miyata, Yasuyoshi, primary, Araki, Kyohei, additional, Ohba, Kojiro, additional, Mastuo, Tomhiro, additional, Nakamura, Yuichiro, additional, Yuno, Tsutomu, additional, Mukai, Yuta, additional, Otsubo, Asato, additional, Mitsunari, Kensuke, additional, Mochizuki, Yasushi, additional, and Sakai, Hideki, additional

Published
2020
Full Text
View/download PDF

8. Pathological roles of c‑Met in bladder cancer: Association with cyclooxygenase‑2, heme oxygenase‑1, vascular endothelial growth factor‑A and programmed death ligand�1

Author

Mukae, Yuta, primary, Miyata, Yasuyoshi, additional, Nakamura, Yuichiro, additional, Araki, Kyohei, additional, Otsubo, Asato, additional, Yuno, Tsutomu, additional, Mitsunari, Kensuke, additional, Matsuo, Tomohiro, additional, Ohba, Kojiro, additional, and Sakai, Hideki, additional

Published
2020
Full Text
View/download PDF

19. Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.

Author

Miyata, Yasuyoshi, Araki, Kyohei, Ohba, Kojiro, Mastuo, Tomhiro, Nakamura, Yuichiro, Yuno, Tsutomu, Mukai, Yuta, Otsubo, Asato, Mitsunari, Kensuke, Mochizuki, Yasushi, and Sakai, Hideki

Subjects
ROYAL jelly, RENAL cell carcinoma, CLINICAL trials
Abstract

Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF- and TGF- in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial Mol Clin Oncol 13:29, 2020; DOI: 10.3892/mco.2020.2099 Following the publication of this article, the authors have realized that, in the Materials and methods section, in the subsection ' I Protocol i ' on p. 2, the second and the final sentences of the second paragraph contained errors: The text in the second paragraph of this subsection should have been written as follows: 'RJ was procured from Yamada Agriculture Center Inc (Okayama, Japan). RJ and placebo were prepared as capsules containing B 800 b mg RJ and starch, respectively. [Extracted from the article]

Published
2020
Full Text
View/download PDF

22. [A CASE OF CONGENITAL UNILATERAL ABSENCE OF THE VAS DEFERENS WITH SUSPECTED IPSILATERAL RENAL AGENESIS].

Author

Harada J, Kihara T, Kawada K, Gono S, Sagawa R, Kondo T, Yuno T, Shida Y, Hakariya T, Kosaka T, Dateki S, Miyata Y, and Sakai H

Abstract

A 5-month-old boy was referred to our department to examine poor development of external genitalia. The patient was diagnosed with micropenis and bilateral impalpable testes, and testosterone replacement therapy was recommended. The testes remained impalpable at 14 months of age; therefore, laparoscopy was performed to explore intra-abdominal testes. The patient was incidentally diagnosed with congenital unilateral absence of the right vas deferens. A renal sonography performed after the operation revealed a high possibility of right renal agenesis. Congenital absence of the vas deferens is associated with a high probability of renal anomalies. It is, therefore, essential to pay careful attention to renal dysfunction.

Published
2021
Full Text
View/download PDF

23. Erratum: Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.

Author

Miyata Y, Araki K, Ohba K, Mastuo T, Nakamura Y, Yuno T, Mukai Y, Otsubo A, Mitsunari K, Mochizuki Y, and Sakai H

Abstract

[This corrects the article DOI: 10.3892/mco.2020.2099.]., (Copyright: © Miyata et al.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results